Risk of metachronous breast cancer after BRCA mutation–associated ovarian cancer. Issue 7 (16th November 2012)

• Record Type: Journal Article
• Authors: Domchek, Susan M.; Jhaveri, Komal; Patil, Sujata; Stopfer, Jill E.; Hudis, Clifford; Powers, Jacquelyn; Stadler, Zsofia; Goldstein, Laura; Kauff, Noah; Khasraw, Mustafa; Offit, Kenneth; Nathanson, Katherine L.; Robson, Mark
• Is Part Of: Cancer. Volume 119:Issue 7(2013)
• Page Start: 1344
• Page End: 1348
• Publication Date: 2012-11-16
• Subjects: Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.27842
• Languages: English
• ISSNs: 0008-543X

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="abs1-1" sec-type="section"> <title>BACKGROUND:</title> <p>This study sought to estimate the risk of breast cancer (BC) after a diagnosis of ovarian cancer (OC) associated with mutation of the <italic>BRCA1/2</italic> (breast cancer, early onset) genes (<italic>BRCA</italic>‐OC).</p> </sec> <sec id="abs1-2" sec-type="section"> <title>METHODS:</title> <p>The Memorial Sloan‐Kettering Cancer Center and the University of Pennsylvania, clinical genetics databases were searched to identify women with <italic>BRCA</italic>‐OC who participated in genetic testing and follow‐up studies from 1995 to 2009. The primary objective was to determine the risk of developing BC after <italic>BRCA</italic>‐OC. Overall survival (OS) and BC‐free survival (BCFS) were determined by the Kaplan‐Meier method; patients were censored at the time of last follow‐up.</p> </sec> <sec id="abs1-3" sec-type="section"> <title>RESULTS:</title> <p>A total of 164 patients had <italic>BRCA</italic>‐OC (115 with <italic>BRCA1</italic>; 49 with <italic>BRCA2</italic>). Of these 164 patients, 152 developed OC prior to <italic>BRCA</italic> testing (median time to testing, 2.4 years [0.01‐55 years]). Median follow‐up from OC for those not developing BC was 5.8 years (0.25‐55.6 years). There were 46 deaths, but none were due to BC. The 5‐ and 10‐year OS were 85% (95% confidence interval [CI] = 0.78, 0.90) and 68% (95% CI = 0.59, 0.76), respectively. There were 18 metachronous BC diagnoses. The 5‐ and 10‐year BCFS were 97% (95% CI = 0.92, 0.99) and 91% (95% CI = 0.82, 0.95), respectively. A subset of 64 women were tested either before or within 12 months of <italic>BRCA</italic>‐OC. In this pseudo‐incident subset, 5‐ and 10‐ year OS was 71% (95% CI = 0.53, 0.83) and 62% (95% CI = 0.44, 0.75), respectively, and 5‐ and 10‐year BCFS were 100% and 87% (95% CI = 0.56, 0.96), respectively.</p> </sec> <sec id="abs1-4" sec-type="section"> <title>CONCLUSIONS:</title> <p>OS was dominated by OC deaths. Metachronous BC risk was lower than reported for unaffected <italic>BRCA</italic> mutation carriers. These results support nonsurgical management of BC risk in women with <italic>BRCA</italic>‐OC. Cancer 2013. © 2012 American Cancer Society.</p> </sec> </abstract>